Skip to main content

Sources last read

FDA report analysis · eight GLP-1 brands

Does a GLP-1 injection hurt?

Injection-site pain appears in FDA reports, but these counts cannot predict how an injection will feel. The term is 11% of Trulicity reports, the largest share among these 8 brands. Ozempic’s term falls outside the stored list.

Source for this answer

Source: FDA side-effect reports, read 2026-08-17

Source: FDA side-effect reports, read 2026-08-17

Trulicity’s measured share exceeds the upper bound for every product where the term is missing. That establishes a difference in report shares, not a difference in patients’ chances of pain.

None of this says how much it hurts, or how long. A report records that somebody named the pain, not what it felt like.

Across FDA reports

Products in the table

8

Carrying the term

5

Known only as a ceiling

3

Highest — Trulicity

11%

Which products have FDA reports for injection site pain

The same term is shown for all eight brands, including the tablet Rybelsus. A report may name several medicines or contain errors. A tablet’s row is not proof that its injection-site report count must be zero.

◆ injection site pain — share of each product’s own reportsShare of that product’s reports
8Exact values — 8 rows in the data table
injection site pain — share of each product’s own reports
ProductShare of that product’s reports
Trulicitydulaglutide11% of Trulicity reports
Mounjarotirzepatide9.8% of Mounjaro reports
Zepboundtirzepatide6.8% of Zepbound reports
Wegovysemaglutide2.8% of Wegovy reports
Ozempicsemaglutidebelow 2.3% of Ozempic reports
Rybelsussemaglutidebelow 2.1% of Rybelsus reports
Saxendaliraglutidebelow 1.9% of Saxenda reports
Victozaliraglutide1.9% of Victoza reports

Hatched, open-ended bars are ceilings rather than measurements. Read from FDA on 2026-08-17.

A dashed row is not a zero. The snapshot keeps each product’s 25 most-reported terms, so a term missing from that list was either never reported or reported and ranked 26th. All this page can prove is that it sits at or below the 25th, and that is what the row says.

Every share above is a share of that product’s own reports. It is never a share of the people who took it, because nobody knows how many that is. Two products can differ here for reasons that have nothing to do with either drug.

What the product rows show

Trulicity has the largest measured share of injection-site pain reports. The totals do not explain the pattern: they contain no comparison of needle size, injection volume or technique.

Wegovy and Ozempic both contain semaglutide. Wegovy has a measured share in this snapshot, while Ozempic’s term is below its cut-off. The shared ingredient does not tell us why the report shares differ.

Rybelsus has no measured injection-site pain row in the saved top terms. That is a limit of the saved data. It does not validate the method, prove a zero count or show which medicine caused an event in a report.

Why a missing row is not the same as none

A missing row means the exact count is not stored. The term may have no reports, or it may fall outside the top 25. The upper bound shows the most the saved data can support.

A top-25 snapshot cannot rank the four brands at the bottom. Their missing rows only mean that pain fell below each product’s reporting cut-off.

Technique is another unanswered question. These totals do not compare the injection site, liquid temperature or speed of injection. They cannot test whether any of those details explain a difference.

What the labels say about it

A label’s injection-site reaction category may include pain alongside other reactions. That grouped figure and this table’s pain-only report share measure different things.

Check the label’s definition before comparing its reaction figure with this table. A trial percentage counts affected people out of all study participants. The report shares here count submitted reports. The percentages cannot be treated as the same measure.

This section summarizes reports people filed. The label guides show what the FDA-approved prescribing information lists. The two answer different questions: what was reported after use, and what was observed in studies.

What this page does and does not establish

These figures describe submitted reports. They do not rank how painful the products are to use.

What each claim is supported by in the report data
The claimWhat the evidence shows
Some GLP-1 products collect far more pain reports than othersEstablished. The top measured share clears the ceiling on every product whose row is a bound.
Ozempic hurts less than MounjaroNot established as a pain rate. FDA data only shows that pain makes up a smaller share of Ozempic reports.
The four brands with no measured row can be rankedNot established. Their shares are all below their own cut-offs, which is not enough to order them.
The tablet’s missing term proves a zero countNot established. The top-25 summary does not give an exact count for Rybelsus, including zero.

Common questions

Which GLP-1 hurts least?

These reports cannot tell us which GLP-1 hurts least. Four products fall below their own reporting cut-offs, so the data cannot rank them.

Is a sore spot afterwards normal?

Injection-site reactions are described in product labels, but a report count cannot assess your sore spot. A pharmacist or clinician can review your symptoms and the product you use.

Does the needle size explain the difference?

Not from this data. The snapshot records a term and a count, with nothing about the needle, the volume or the person. Any mechanism here would be a story laid over the numbers.

Where to go next

This page is one question asked of one snapshot. The pages below answer the neighboring ones from the labels and the trials, which is a different kind of evidence.

Every question in this section is listed on the report-stream questions index.

Read this before quoting anything above

These are counts of reports filed with the FDA, not rates among people treated. This data does not count everyone who used the drug, and a report does not establish that the drug caused the event.

  • No count of everyone treated. FAERS counts submitted reports, not everyone who used a drug. Each percentage here divides an event count by the drug’s report total. It describes a share of reports, not a share of people treated or their chance of an event.
  • A report is not proof the drug did it. FDA does not require proof that a drug caused an event before accepting a report. The drug, an illness or another factor may be involved. A report naming both a drug and an event does not establish the cause.
  • A bigger number can just mean a more-prescribed drug. More reports can simply mean that more people use the drug, that it is newer, or that it receives more news and legal attention. Raw report totals do not tell you which drug is safer.
  • The same event can be counted twice. One event can reach FAERS through more than one channel — the patient, the prescriber and the manufacturer can all file. FDA does not guarantee that the public files are de-duplicated.
  • FDA’s own words. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
  • Retrieved 2026-08-17 from https://api.fda.gov/drug/event.json · FDA data last updated 2026-07-30 · license https://open.fda.gov/license/

How everything on this site is sourced →

10primary sources, each with the day we read it — open the documents used on this page